Hepatogastroenterology

Bixia Liu(Zhejiang Cancer Hospital), Haijun Zhong(Zhejiang Cancer Hospital), Cong Luo(Chongqing University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Qi Xu
Hepatogastroenterology
February 13, 2012
10.5754/hge11893
Cited by 1,342

Related Papers

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
|The Lancet Oncology|2023|264
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
|癌症：英文版|2021|207